FORA Capital LLC purchased a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 27,744 shares of the biotechnology company's stock, valued at approximately $1,116,000.
Several other institutional investors and hedge funds have also modified their holdings of VKTX. Principal Financial Group Inc. raised its position in shares of Viking Therapeutics by 29.9% during the third quarter. Principal Financial Group Inc. now owns 593,528 shares of the biotechnology company's stock valued at $37,576,000 after buying an additional 136,729 shares during the last quarter. Eagle Bay Advisors LLC bought a new position in shares of Viking Therapeutics in the fourth quarter valued at about $92,000. Salem Investment Counselors Inc. lifted its position in Viking Therapeutics by 557.8% during the 4th quarter. Salem Investment Counselors Inc. now owns 3,289 shares of the biotechnology company's stock worth $132,000 after buying an additional 2,789 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its holdings in Viking Therapeutics by 600.0% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,500 shares of the biotechnology company's stock worth $141,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Wolff Wiese Magana LLC acquired a new stake in Viking Therapeutics in the 4th quarter valued at about $75,000. Institutional investors and hedge funds own 76.03% of the company's stock.
Insider Activity at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan purchased 1,240 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the purchase, the director now directly owns 1,240 shares in the company, valued at approximately $29,946. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by insiders.
Wall Street Analyst Weigh In
VKTX has been the topic of several recent research reports. Scotiabank initiated coverage on shares of Viking Therapeutics in a research note on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday, April 24th. B. Riley restated a "buy" rating and issued a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. Citigroup started coverage on Viking Therapeutics in a research report on Friday, February 7th. They set a "neutral" rating and a $38.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on Viking Therapeutics in a report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price target for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Viking Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.15.
View Our Latest Analysis on Viking Therapeutics
Viking Therapeutics Price Performance
NASDAQ:VKTX traded up $0.11 during trading hours on Thursday, reaching $26.68. 1,269,222 shares of the company were exchanged, compared to its average volume of 4,107,425. The company has a market capitalization of $3.00 billion, a P/E ratio of -26.66 and a beta of 0.75. The business has a 50 day moving average of $26.12 and a 200 day moving average of $37.24. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $81.73.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.26) EPS. As a group, equities research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
About Viking Therapeutics
(
Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
